Immunome Stock Current Ratio
| IMNM Stock | USD 9.82 0.40 4.25% |
Immunome fundamentals help investors to digest information that contributes to Immunome's financial success or failures. It also enables traders to predict the movement of Immunome Stock. The fundamental analysis module provides a way to measure Immunome's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immunome stock.
| Last Reported | Projected for Next Year | ||
| Current Ratio | 6.63 | 4.38 |
Immunome | Current Ratio |
Immunome Company Current Ratio Analysis
Immunome's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Immunome Current Ratio | 4.36 X |
Most of Immunome's fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immunome is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Immunome Current Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Immunome is extremely important. It helps to project a fair market value of Immunome Stock properly, considering its historical fundamentals such as Current Ratio. Since Immunome's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Immunome's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Immunome's interrelated accounts and indicators.
Click cells to compare fundamentals
Immunome Current Ratio Historical Pattern
Today, most investors in Immunome Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Immunome's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current ratio growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Immunome current ratio as a starting point in their analysis.
Immunome Current Ratio |
| Timeline |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
In accordance with the recently published financial statements, Immunome has a Current Ratio of 4.36 times. This is 49.83% higher than that of the Biotechnology sector and 37.71% lower than that of the Health Care industry. The current ratio for all United States stocks is 101.85% lower than that of the firm.
Immunome Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immunome's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immunome could also be used in its relative valuation, which is a method of valuing Immunome by comparing valuation metrics of similar companies.Immunome is currently under evaluation in current ratio category among its peers.
Immunome Current Valuation Drivers
We derive many important indicators used in calculating different scores of Immunome from analyzing Immunome's financial statements. These drivers represent accounts that assess Immunome's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Immunome's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 77.3M | 97.9M | 149.5M | 26.8M | 212.3M | 222.9M | |
| Enterprise Value | 75.3M | 58.7M | 100.6M | 6.8M | 115.3M | 121.1M |
Immunome ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Immunome's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Immunome's managers, analysts, and investors.Environmental | Governance | Social |
Immunome Fundamentals
| Return On Equity | -2.76 | ||||
| Return On Asset | -0.4 | ||||
| Operating Margin | (15.06) % | ||||
| Current Valuation | 375.52 M | ||||
| Shares Outstanding | 62.42 M | ||||
| Shares Owned By Insiders | 16.77 % | ||||
| Shares Owned By Institutions | 83.47 % | ||||
| Number Of Shares Shorted | 10.47 M | ||||
| Price To Book | 2.74 X | ||||
| Price To Sales | 60.51 X | ||||
| Revenue | 14.02 M | ||||
| EBITDA | (28.27 M) | ||||
| Net Income | (106.81 M) | ||||
| Cash And Equivalents | 34.65 M | ||||
| Cash Per Share | 2.86 X | ||||
| Total Debt | 1.65 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 4.36 X | ||||
| Book Value Per Share | 4.97 X | ||||
| Cash Flow From Operations | (7.57 M) | ||||
| Short Ratio | 18.28 X | ||||
| Earnings Per Share | (7.94) X | ||||
| Target Price | 30.0 | ||||
| Number Of Employees | 55 | ||||
| Beta | 1.82 | ||||
| Market Capitalization | 612.93 M | ||||
| Total Asset | 148.54 M | ||||
| Retained Earnings | (222.81 M) | ||||
| Working Capital | 122.87 M | ||||
| Net Asset | 148.54 M |
About Immunome Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immunome's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunome using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunome based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Immunome Piotroski F Score and Immunome Altman Z Score analysis. To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunome. If investors know Immunome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunome listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.94) | Revenue Per Share 0.189 | Quarterly Revenue Growth (0.18) | Return On Assets (0.40) | Return On Equity (2.76) |
The market value of Immunome is measured differently than its book value, which is the value of Immunome that is recorded on the company's balance sheet. Investors also form their own opinion of Immunome's value that differs from its market value or its book value, called intrinsic value, which is Immunome's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunome's market value can be influenced by many factors that don't directly affect Immunome's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunome's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunome is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunome's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.